Quantitative SPECT/CT imaging of actinium-225 for targeted alpha therapy of
glioblastomas.
A new, alternative option for patients with recurrent glioblastoma is targeted alpha therapy (TAT), in the form of a local administration of substance P (neurokinin type 1 receptor ligand, NK-1) labelled with 225Ac. The purpose of the study was to confirm the feasibility of quantitative SPECT imaging of 225Ac, in a model reproducing specific conditions of TAT. In particular, to present the SPECT calibration methodology used, as well as the results of validation measurements and their accuracy. Additionally, to discuss the specific problems related to high noise in the presented case.
TULIK Monika;
KULINSKI Radoslaw;
TABOR Zbislaw;
BRZOZOWSKA Beata;
LABA P.;
BRUCHERTSEIFER Frank;
MORGENSTERN Alfred;
KROLICKI Leszek;
KUNIKOWSKA Jolanta;
2024-07-24
SPRINGER
JRC135184
2197-7364 (online),
https://ejnmmiphys.springeropen.com/articles/10.1186/s40658-024-00635-1,
https://publications.jrc.ec.europa.eu/repository/handle/JRC135184,
10.1186/s40658-024-00635-1 (online),
Additional supporting files
| File name | Description | File type | |
|---|
